Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Nawwar Al-Attar
Carotid endarterectomy is the standard treatment for atherosclerotic stenosis of the internal carotid artery. Carotid angioplasty is gaining increasing popularity as a less invasive technique in symptomatic patients with severe (>70%) carotid artery stenosis especially in those with significant co-morbidities.
Carotid endarterectomy has established benefits when compared to medical treatment in the management of symptomatic and asymptomatic internal carotid artery stenosis.
Surgery provides a significant reduction of the long term risk of stroke or death in symptomatic patients with =70% stenosis of the internal carotid artery when compared to medical treatment. In NASCET (North American Symptomatic Carotid Endarterectomy Trial), symptomatic patients with severe carotid stenosis were randomised to medical treatment or carotid endarterectomy (1). In the surgical group,
In symptomatic patients with moderate (58%–69%) stenosis, surgery has also demonstrated a superior risk reduction when compared to medical treatment (6).
Surgery provided superior results when compared to medical treatment in the Asymptomatic Carotid Atherosclerosis Study which included 1662 patients with asymptomatic carotid artery stenosis in patients with carotid artery stenosis >60%.
The long term benefits of carotid endarterectomy for both symptomatic and asymptomatic patients need to be weighed against the immediate risk of complications of the procedure, thus benefit is tangible only in the presence of a low perioperative complication rate. The surgical procedure should be performed by an experienced surgeon with good patient selection and as such continues to be the gold standard.
Carotid angioplasty has evolved with procedural technologic advancements supplemented by the introduction of intravascular stents and new antiplatelet drugs. The SAPPHIRE trial (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) had concluded that carotid-artery stenting was not inferior to endarterectomy with a lower risk of myocardial infarction within 30 days after carotid stenting.
Subsequent studies such as SPACE (Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy) gave contradictory results.
In the EVA-3S study (Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis)
A meta-analysis of 5 randomised clinical trials revealed a periprocedural complication rate (stroke and death within 30 days) of 8.1% in the carotid stenting group and 6.3% in the endarterectomy group (12).
The use of embolic protection devices has been shown to reduce thromboembolic complications and increase the safety of carotid-artery stenting. However, this remains a continuing debate (13).
Patients should be informed that there are insufficient data for long-term comparison between carotid angioplasty and surgery. Stenting does not seem to be safer than surgery despite a small difference between the two treatments in the order of 4 events in 600 patients per group. The US Food and Drug Administration advocates stenting only in symptomatic patients with stenosis of the internal carotid artery >70% who are at high risk for complications after surgery.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. The beneficial effects of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-53. 2. Ferguson GG, Eliasziw M, Barr HW, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke 1999;30:1751-8 3. Paciaroni M, Eliasziw M, Kappelle J, et al. Medical complications associated with carotid endarterectomy.North American Symptomatic Carotid Endarterectomy Trial. Stroke 1999;30:1759-63. 4. European Carotid Surgery Trialists Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379-87. 5. Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis: Veterans Affairs Cooperative Studies Program 309 Trialists Group. JAMA 1991;266:3289-94. 6. Barnett HJM, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415-25. 7. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for symptomatic carotid artery stenosis. JAMA 1995;273:1421-8. 8. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491-1502. 9. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotidartery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493-501. 10. SPACE Collaborative Group; Ringleb PA, Allenberg J, Bruckmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006;368:1239-47. 11. Mas JL, Chatellier G, Beyssen B, et al; EVA-3S Investigators. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660-71. 12. Coward LJ, Featherstone RL, Brown MM. Safety and efficacy of endovascular treatment of carotid artery stenosis compared with carotid endarterectomy: a Cochrane systematic review of the randomized evidence. Stroke 2005;36:905–11. 13. Kastrup A, Groschel K, Krapf H, et al. Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. Stroke 2003;34:813–19.
Prof. N. Al-Attar Paris, France Web editor of the Working Group on Cardiovascular Surgery
© 2017 European Society of Cardiology. All rights reserved